LU88670I2 - Fluvastatine eventuellement sous forme de sel par exemple sel de sodium - Google Patents

Fluvastatine eventuellement sous forme de sel par exemple sel de sodium

Info

Publication number: LU88670I2
Authority: LU; Luxembourg
Prior art keywords: hydrogen; benzyloxy; phenoxy; trifluoromethyl; fluoro
Prior art date: 1982-11-22

Application number

LU88670C

Other languages

English (en)

Original Assignee

Sandoz Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-11-22

Filing date

1983-11-22

Publication date

1996-04-29

1983-11-22 Application filed by Sandoz Ag filed Critical Sandoz Ag

1996-04-29 Publication of LU88670I2 publication Critical patent/LU88670I2/fr

Links

150000003839 salts Chemical class 0.000 title abstract 2
ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 title 1
229960003765 fluvastatin Drugs 0.000 title 1
159000000000 sodium salts Chemical class 0.000 title 1
229910052739 hydrogen Inorganic materials 0.000 abstract 12
239000001257 hydrogen Substances 0.000 abstract 12
150000002431 hydrogen Chemical group 0.000 abstract 7
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 6
-1 t-butoxy Chemical group 0.000 abstract 6
125000001153 fluoro group Chemical group F* 0.000 abstract 5
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 4
125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 3
125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 2
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
125000001309 chloro group Chemical group Cl* 0.000 abstract 1
235000012000 cholesterol Nutrition 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
150000002596 lactones Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Pharmacology & Pharmacy (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Obesity (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Indole Compounds (AREA)
Saccharide Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Plural Heterocyclic Compounds (AREA)
Pyrane Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

LU88670C 1982-11-22 1983-11-22 Fluvastatine eventuellement sous forme de sel par exemple sel de sodium LU88670I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US44366882A	1982-11-22	1982-11-22
US54885083A	1983-11-04	1983-11-04

Publications (1)

Publication Number	Publication Date
LU88670I2 true LU88670I2 (fr)	1996-04-29

Family

ID=27033614

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU88670C LU88670I2 (fr)	1982-11-22	1983-11-22	Fluvastatine eventuellement sous forme de sel par exemple sel de sodium

Country Status (18)

Country	Link
EP (1)	EP0114027B1 (fr)
JP (1)	JPH0347167A (fr)
AT (1)	ATE31718T1 (fr)
AU (1)	AU570021B2 (fr)
CA (1)	CA1210405A (fr)
CY (1)	CY1579A (fr)
DE (2)	DE19475017I2 (fr)
DK (2)	DK359284A (fr)
FI (1)	FI77228C (fr)
GR (1)	GR79042B (fr)
HK (1)	HK11191A (fr)
HU (1)	HU204253B (fr)
IE (1)	IE56262B1 (fr)
IL (1)	IL70286A (fr)
LU (1)	LU88670I2 (fr)
NL (1)	NL950022I2 (fr)
NZ (1)	NZ206338A (fr)
WO (1)	WO1984002131A1 (fr)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5354772A (en) *	1982-11-22	1994-10-11	Sandoz Pharm. Corp.	Indole analogs of mevalonolactone and derivatives thereof
US4613610A (en) *	1984-06-22	1986-09-23	Sandoz Pharmaceuticals Corp.	Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
DE3581638D1 (de) *	1984-12-04	1991-03-07	Sandoz Ag	Inden-analoga von mevalonolakton und ihre derivate.
US5001255A (en) *	1984-12-04	1991-03-19	Sandoz Pharm. Corp.	Idene analogs of mevalonolactone and derivatives thereof
US4668794A (en) *	1985-05-22	1987-05-26	Sandoz Pharm. Corp.	Intermediate imidazole acrolein analogs
KR900001212B1 (ko) *	1985-10-25	1990-02-28	산도즈 파마슈티칼스 코오포레이숀	메바로노락톤 및 그것의 유도체의 헤테로사이클릭 유사체 및 그것의 생산방법 및 약학적인 그것의 용도
US4851427A (en) *	1985-10-25	1989-07-25	Sandoz Pharm. Corp.	Pyrrole analogs of mevalonolactone, derivatives thereof and pharmaceutical use
NZ221717A (en) *	1986-09-10	1990-08-28	Sandoz Ltd	Azaindole and indolizine derivatives and pharmaceutical compositions
US4751235A (en) *	1986-12-23	1988-06-14	Sandoz Pharm. Corp.	Anti-atherosclerotic indolizine derivatives
US4735958A (en) *	1986-12-22	1988-04-05	Warner-Lambert Company	Trans-6-[2-[2-(substituted-phenyl)-3- (or 4-) heteroaryl-5-substituted-1H-pyrrol-1-yl]-ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one inhibitors of cholesterol biosynthesis
US4898949A (en) *	1987-02-25	1990-02-06	Bristol-Myers Company	Intermediates for the preparation of antihypercholesterolemic tetrazole compounds
US4897490A (en) *	1987-02-25	1990-01-30	Bristol-Meyers Company	Antihypercholesterolemic tetrazole compounds
US4894386A (en) *	1987-04-15	1990-01-16	Ici Americas Inc.	Aliphatic carboxamides
US4904646A (en) *	1987-05-22	1990-02-27	E. R. Squibb & Sons, Inc.	Phosphorus-containing HMG-COA reductase inhibitors
US5091378A (en) *	1987-05-22	1992-02-25	E. R. Squibb & Sons, Inc.	Phosphorus-containing HMG-CoA reductase inhibitors, new intermediates and method
JP2569746B2 (ja) *	1987-08-20	1997-01-08	日産化学工業株式会社	キノリン系メバロノラクトン類
CA1336714C (fr) *	1987-08-20	1995-08-15	Yoshihiro Fujikawa	Mevalonolactone de type quinoleine utilisee comme inhibiteurs de la biosynthese du cholesterol
US5185328A (en) *	1987-08-20	1993-02-09	Nissan Chemical Industries Ltd.	Quinoline type mevalonolactones useful for treating hyperlipidemia, hyperlipoproteinemia or atherosclerosis
DE3739882A1 (de) *	1987-11-25	1989-06-08	Bayer Ag	Substituierte hydroxylamine
US4868185A (en) *	1987-12-10	1989-09-19	Warner-Lambert Company	6-[[Substituted)pyrimidinyl)ethyl]- and ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
EP0326386A3 (fr) *	1988-01-27	1990-04-25	May & Baker Limited	Isoquinoléinones
US4822799A (en) *	1988-01-27	1989-04-18	Sandoz Pharm. Corp.	Pyrazolopyridine analogs of mevalonolactone and derivatives thereof useful for inhibiting cholesterol biosynthesis in mammals
NO890522L (no) *	1988-02-25	1989-08-28	Bayer Ag	Substituerte imidazolinoner og imidazolinthioner.
US5024999A (en) *	1988-04-26	1991-06-18	Nissan Chemical Industries Ltd.	Pyrazolopyridine type mevalonolactones useful as pharmaeuticals
JP2890448B2 (ja) *	1988-04-26	1999-05-17	日産化学工業株式会社	ピラゾロピリジン系メバロノラクトン類
US4870187A (en) *	1988-08-23	1989-09-26	Bristol-Myers Company	Antihypercholesterolemic tetrazol-1-yl compounds
US5010205A (en) *	1988-08-23	1991-04-23	Bristol-Myers Company	Antihypercholesterolemic tetrazol-1-yl intermediates
NZ230121A (en) *	1988-08-29	1993-08-26	Squibb & Sons Inc	Pyridine and quinoline terminal groups for hmg-coenzyme a reductase inhibitors and pharmaceutical compositions for lowering blood serum cholesterol levels
US5506219A (en) *	1988-08-29	1996-04-09	E. R. Squibb & Sons, Inc.	Pyridine anchors for HMG-CoA reductase inhibitors
DE68911834T2 (de) *	1988-10-13	1994-06-23	Sandoz Ag	Verfahren zur Herstellung von 7-substituierten Hept-6-en- und Heptansäuren und Derivaten davon.
JPH04270285A (ja) *	1988-11-14	1992-09-25	Nissan Chem Ind Ltd	ピラゾロピリミジン系メバロノラクトン類
DE3911064A1 (de) *	1989-04-06	1990-10-11	Bayer Ag	Substituierte 1,8-naphthyridine
FI94339C (fi)	1989-07-21	1995-08-25	Warner Lambert Co	Menetelmä farmaseuttisesti käyttökelpoisen /R-(R,R)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
GB8919091D0 (en) *	1989-08-22	1989-10-04	Fujisawa Pharmaceutical Co	Pyrroloquinoline compounds
IT1237792B (it) *	1989-12-21	1993-06-17	Zambon Spa	Composti attivi come inibitori dell'enzima hmg-coa reduttasi
HU9203780D0 (en) *	1991-12-12	1993-03-29	Sandoz Ag	Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
DE4243279A1 (de) *	1992-12-21	1994-06-23	Bayer Ag	Substituierte Triole
JP2736599B2 (ja) *	1993-07-23	1998-04-02	株式会社キッツ	ボールバルブのシート構造
US6425881B1 (en)	1994-10-05	2002-07-30	Nitrosystems, Inc.	Therapeutic mixture useful in inhibiting lesion formation after vascular injury
WO1997049681A1 (fr) *	1996-06-24	1997-12-31	Astra Aktiebolag (Publ)	Composes polymorphes
AU7550398A (en)	1997-06-05	1998-12-21	Takeda Chemical Industries Ltd.	Heterocyclic compounds, their production and use
NZ511792A (en)	1998-11-20	2003-08-29	Skyepharma Canada Inc	Dispersible phospholipid stabilized microparticles
US6242003B1 (en)	2000-04-13	2001-06-05	Novartis Ag	Organic compounds
AU2001274049A1 (en)	2000-05-26	2001-12-11	Ciba Specialty Chemicals Holding Inc.	Process for the preparation of indole derivatives and intermediates of the process
US20060127474A1 (en)	2001-04-11	2006-06-15	Oskar Kalb	Pharmaceutical compositions comprising fluvastatin
JP2004526778A (ja)	2001-04-18	2004-09-02	ジェンザイムコーポレーション	脂肪族ポリアミンを用いるｘ症候群の処置方法
RU2334738C2 (ru) *	2001-08-03	2008-09-27	Циба Спешиалти Кемикэлз Холдинг Инк.	Кристаллические формы
EP1465882B1 (fr)	2001-12-21	2011-08-24	X-Ceptor Therapeutics, Inc.	Modulateurs heterocycliques de recepteurs nucleaires
CA2480879A1 (fr)	2002-04-12	2003-10-23	Merck & Co., Inc.	Inhibiteurs de tyrosines kinases
JP4553899B2 (ja)	2003-08-21	2010-09-29	メルクフロストカナダリミテツド	カテプシンシステインプロテアーゼ阻害剤
EP1510208A1 (fr)	2003-08-22	2005-03-02	Fournier Laboratories Ireland Limited	Compositions pharmaceutiques comprenant une combinaison de metformine et de statine
CN100404479C (zh) *	2003-08-27	2008-07-23	住友化学株式会社	芳族不饱和化合物的制备方法
US8227434B1 (en)	2003-11-04	2012-07-24	H. Lee Moffitt Cancer Center & Research Institute, Inc.	Materials and methods for treating oncological disorders
US7709508B2 (en)	2004-12-09	2010-05-04	Merck Sharp & Dohme	Estrogen receptor modulators
US7511152B2 (en) *	2004-12-09	2009-03-31	Merck & Co., Inc.	Estrogen receptor modulators
US8722734B2 (en)	2005-03-02	2014-05-13	Merck Sharp & Dohme Corp.	Composition for inhibition of cathepsin K
MX2008000141A (es)	2005-06-27	2008-04-07	Exelixis Inc	Moduladores de lxr basados en imidazol.
WO2007017117A1 (fr) *	2005-07-28	2007-02-15	Lek Pharmaceuticals D.D.	Processus destine a la synthese de calcium rosuvastatine
US8440695B2 (en)	2005-11-09	2013-05-14	St Jude Children's Research Hospital	Use of chloroquine to treat metabolic syndrome
KR101464385B1 (ko)	2006-04-19	2014-11-21	노파르티스 아게	６-ｏ-치환된 벤즈옥사졸 및 벤조티아졸 화합물, 및 ｃｓｆ-１ｒ 신호전달의 억제 방법
DE602006006899D1 (de)	2006-04-20	2009-07-02	Italiana Sint Spa	Verfahren zur Herstellung von Fluvastatin-Natrium
UA98466C2 (uk)	2006-07-05	2012-05-25	Нікомед Гмбх	КОМБІНАЦІЯ ІНГІБІТОРА HMG-CоA-РЕДУКТАЗИ Й ІНГІБІТОРА ФОСФОДІЕСТЕРАЗИ 4, ПРИЗНАЧЕНА ДЛЯ ЛІКУВАННЯ ЗАПАЛЬНИХ ЗАХВОРЮВАНЬ ЛЕГЕНІВ
US20110218176A1 (en)	2006-11-01	2011-09-08	Barbara Brooke Jennings-Spring	Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
JP5330274B2 (ja)	2007-03-01	2013-10-30	ノバルティスアーゲー	Ｐｉｍキナーゼ阻害剤およびその使用方法
AU2008254425A1 (en)	2007-05-21	2008-11-27	Novartis Ag	CSF-1R inhibitors, compositions, and methods of use
ES2330184B1 (es)	2008-06-03	2010-07-05	Neuron Biopharma, S.A.	Uso de estatinas como anticonvulsivantes, antiepilepticos y neuroprotectores.
WO2010069593A1 (fr)	2008-12-19	2010-06-24	Krka, D. D., Novo Mesto	Utilisation de composés amphiphiles pour la cristallisation régulée de statines et d'intermédiaires de statines
EP2327682A1 (fr)	2009-10-29	2011-06-01	KRKA, D.D., Novo Mesto	Utilisation de composés amphiphiles pour la crystallisation controlée de statines et d'intermediaires de statines.
AU2010254082B2 (en)	2009-05-28	2015-01-29	Exelixis, Inc.	LXR modulators
US8765747B2 (en)	2009-06-12	2014-07-01	Dana-Farber Cancer Institute, Inc.	Fused 2-aminothiazole compounds
US9180127B2 (en)	2009-12-29	2015-11-10	Dana-Farber Cancer Institute, Inc.	Type II Raf kinase inhibitors
KR20130006664A (ko)	2010-03-16	2013-01-17	다나-파버 캔서 인스티튜트 인크.	인다졸 화합물 및 그의 용도
US8372877B2 (en)	2010-04-16	2013-02-12	Cumberland Pharmaceuticals	Stabilized statin formulations
CN103153299A (zh)	2010-10-06	2013-06-12	国立大学法人东京大学	淋巴水肿预防治疗剂
WO2012112363A1 (fr)	2011-02-14	2012-08-23	Merck Sharp & Dohme Corp.	Inhibiteurs de cystéine protéases, les cathepsines
AR088728A1 (es)	2011-03-25	2014-07-02	Bristol Myers Squibb Co	Moduladores de lxr como prodroga de imidazol
WO2013074986A1 (fr)	2011-11-17	2013-05-23	Dana-Farber Cancer Institute, Inc.	Inhibiteurs de la kinase c-jun-n-terminale (jnk)
WO2013102193A1 (fr)	2011-12-29	2013-07-04	Trustees Of Tufts College	Fonctionnalisation de biomatériaux pour commander la régénération et des réponses à une inflammation
EP2909194A1 (fr)	2012-10-18	2015-08-26	Dana-Farber Cancer Institute, Inc.	Inhibiteurs de cycline-dépendante kinase 7 (cdk7)
WO2014063054A1 (fr)	2012-10-19	2014-04-24	Dana-Farber Cancer Institute, Inc.	Inhibiteurs de kinase moelle osseuse sur chromosome x (bmx) et leurs utilisations
US9758522B2 (en)	2012-10-19	2017-09-12	Dana-Farber Cancer Institute, Inc.	Hydrophobically tagged small molecules as inducers of protein degradation
EP2968275B1 (fr)	2013-03-15	2017-11-29	Bristol-Myers Squibb Company	Modulateurs des lxr
EP2810644A1 (fr)	2013-06-06	2014-12-10	Ferrer Internacional, S.A.	Formulation orale pour le traitement de maladies cardiovasculaires
WO2015051479A1 (fr)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Inhibiteurs de cystéine-protéases de type cathepsines
JP6454335B2 (ja)	2013-10-08	2019-01-16	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	カテプシンシステインプロテアーゼ阻害剤
CA2927917C (fr)	2013-10-18	2022-08-09	Syros Pharmaceuticals, Inc.	Composes heteroaromatiques utiles pour le traitement des maladies proliferatives
AU2014337044A1 (en)	2013-10-18	2016-05-05	Dana-Farber Cancer Institute, Inc.	Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2015120580A1 (fr)	2014-02-11	2015-08-20	Merck Sharp & Dohme Corp.	Inhibiteurs de protéases à cystéine de type cathépsines
WO2015164604A1 (fr)	2014-04-23	2015-10-29	Dana-Farber Cancer Institute, Inc.	Inhibiteurs de janus kinase marqués de manière hydrophobe et utilisations associées
WO2015164614A1 (fr)	2014-04-23	2015-10-29	Dana-Farber Cancer Institute, Inc.	Inhibiteurs de janus kinase et leurs utilisations
JO3589B1 (ar)	2014-08-06	2020-07-05	Novartis Ag	مثبطات كيناز البروتين c وطرق استخداماتها
CA2972239A1 (fr)	2014-12-23	2016-06-30	Dana-Farber Cancer Institute, Inc.	Inhibiteurs de la kinase cycline-dependante 7 (cdk7)
EP3273966B1 (fr)	2015-03-27	2023-05-03	Dana-Farber Cancer Institute, Inc.	Inhibiteurs de kinases cycline-dépendantes
AU2016276963C1 (en)	2015-06-12	2021-08-05	Dana-Farber Cancer Institute, Inc.	Combination therapy of transcription inhibitors and kinase inhibitors
WO2017044858A2 (fr)	2015-09-09	2017-03-16	Dana-Farber Cancer Institute, Inc.	Inhibiteurs de kinases cycline-dépendantes

1983
- 1983-11-18 WO PCT/EP1983/000308 patent/WO1984002131A1/fr active IP Right Grant
- 1983-11-18 AU AU22612/83A patent/AU570021B2/en not_active Expired
- 1983-11-18 HU HU84284A patent/HU204253B/hu unknown
- 1983-11-21 GR GR73028A patent/GR79042B/el unknown
- 1983-11-21 IE IE2713/83A patent/IE56262B1/en not_active IP Right Cessation
- 1983-11-21 NZ NZ206338A patent/NZ206338A/en unknown
- 1983-11-21 IL IL70286A patent/IL70286A/xx not_active IP Right Cessation
- 1983-11-22 DE DE1994175017 patent/DE19475017I2/de active Active
- 1983-11-22 DE DE8383810548T patent/DE3375137D1/de not_active Expired
- 1983-11-22 LU LU88670C patent/LU88670I2/fr unknown
- 1983-11-22 EP EP83810548A patent/EP0114027B1/fr not_active Expired
- 1983-11-22 CA CA000441684A patent/CA1210405A/fr not_active Expired
- 1983-11-22 AT AT83810548T patent/ATE31718T1/de active
1984
- 1984-06-28 FI FI842615A patent/FI77228C/fi not_active IP Right Cessation
- 1984-07-20 DK DK359284A patent/DK359284A/da not_active Application Discontinuation
1990
- 1990-04-19 DK DK097890A patent/DK165244C/da not_active IP Right Cessation
- 1990-05-11 JP JP2120164A patent/JPH0347167A/ja active Granted
1991
- 1991-02-06 HK HK111/91A patent/HK11191A/xx not_active IP Right Cessation
- 1991-12-20 CY CY1579A patent/CY1579A/xx unknown
1995
- 1995-09-28 NL NL950022C patent/NL950022I2/nl unknown

Also Published As

Publication number	Publication date
DE3375137D1 (en)	1988-02-11
AU570021B2 (en)	1988-03-03
FI77228B (fi)	1988-10-31
DK97890D0 (da)	1990-04-19
CA1210405A (fr)	1986-08-26
IE832713L (en)	1984-05-22
NL950022I2 (nl)	1996-12-02
WO1984002131A1 (fr)	1984-06-07
ATE31718T1 (de)	1988-01-15
CY1579A (en)	1991-12-20
DE19475017I2 (de)	2003-02-20
DK359284D0 (da)	1984-07-20
HUT35642A (en)	1985-07-29
FI842615A0 (fi)	1984-06-28
DK359284A (da)	1984-07-20
EP0114027B1 (fr)	1988-01-07
DK97890A (da)	1990-04-19
FI842615A (fi)	1984-06-28
NL950022I1 (fr)	1996-01-02
AU2261283A (en)	1984-06-18
IL70286A (en)	1987-08-31
GR79042B (fr)	1984-10-02
HK11191A (en)	1991-02-13
DK165244C (da)	1993-03-22
JPH0440343B2 (fr)	1992-07-02
FI77228C (fi)	1989-02-10
IE56262B1 (en)	1991-06-05
IL70286A0 (en)	1984-02-29
DK165244B (da)	1992-10-26
EP0114027A1 (fr)	1984-07-25
HU204253B (en)	1991-12-30
JPH0347167A (ja)	1991-02-28
NZ206338A (en)	1987-08-31

Publication	Publication Date	Title
LU88670I2 (fr)	1996-04-29	Fluvastatine eventuellement sous forme de sel par exemple sel de sodium
NZ214402A (en)	1989-01-27	Indene derivatives and pharmaceutical compositions
PT80674B (en)	1987-03-17	Process for the preparation of pyrazole analogues of mevalonolactone and derivatives thereof
ES8102561A1 (es)	1981-02-16	Procedimiento de preparacion de los aril-1 arilsulfonil-4 a amino-propoxi-3 1h pirazoles
ES8702371A1 (es)	1986-12-16	Un procedimiento para preparar nuevos derivados de 6-(4-fenilo sustituido -3(2h) piradazinona.
DE3067201D1 (en)	1984-04-26	Quinazoline derivatives, processes for their preparation and pharmaceutical compositions containing them
GB8530602D0 (en)	1986-01-22	Heterocyclic compounds
AU555818B2 (en)	1986-10-09	Amino hydroxy proprophenones pharmaceutical use
ES2010284A6 (es)	1989-11-01	Procedimiento para preparar derivados de tiourea.
ES8708220A1 (es)	1987-10-01	Procedimiento para la obtencion de halogeno-hidroxi-flavonas
GB2160525A (en)	1985-12-24	8,10-dideazaminopterins
ES482949A1 (es)	1980-07-01	Un procedimiento para la preparacion de compuestos derivadosde piridoxina
IL61769A0 (en)	1981-01-30	2-phenylamino-imidazolines-(2),their preparation and pharmaceutical compositions containing them
EP0086756A3 (fr)	1984-11-28	Compositions dermatologiques basées sur des thiolesters mercaptopropionylamidoacétiques
DE69405999D1 (de)	1997-11-06	Pharmazeutisch wirksame enantiomere
ES8500619A1 (es)	1984-11-01	Procedimiento de preparacion de derivados de eburnano-oxima racemicos u opticamente activos.
ES489925A1 (es)	1980-10-01	Procedimiento para la preparacion de n,n'-difenil-monohidra-zida de acido 2-(3-metil-3-butenil)-malonico
ES8506660A1 (es)	1985-08-01	Un procedimiento para la preparacion de un compuesto de b-lactama